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be investigated further (figure). If clinical features suggest 
a  more pressing need for investigation (such as jaundice or 
raised bilirubin, deranged clotting, or hepatic decompensa-
tion) investigation should be expedited.
All patients found to have raised serum alanine 
a minotransferase should have serum aspartate aminotrans-
ferase and γ glutamyltransferase measured. The ratio of 
aspartate aminotransferase to alanine aminotransferase 
may provide information about the likely aetiology of the 
liver disease2; a ratio >2 is suggestive but not diagnostic 
of alcohol related liver disease, a ratio of <1 typically sug-
gests hepatic steatosis or chronic viral hepatitis. Raised γ 
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How do you approach the investigation of a 
patient with mildly abnormal aminotransferase 
tests? This article will guide you through 
diagnosis and assessment of severity
A 43 year old man of South Asian origin, working as a 
software engineer, was found to have a serum alanine 
aminotransferase value of 64 (normal range 0-40) U/l at a 
routine health check arranged by his company. He had an 
unremarkable medical history and took no regular medica-
tions. Of note, his father had died of ischaemic heart disease 
at the age of 67 years. Clinical examination was unremark-
able. His height was 1.7 m and weight 79 kg (body mass 
index 27). The results of the remaining basic liver blood 
tests were normal (bilirubin 12 (0-20) μmol/l; alkaline 
phosphatase 105 (30-150) U/l; albumin 38 (35-50) g/l). 
Full blood count and serum urea, creatinine, and electro-
lytes were also within normal limits.
What is the next investigation?
An initial history and clinical examination are necessary 
for determining the likely aetiology of the raised alanine 
aminotransferase value, the presence of any comorbidity 
that may accelerate disease progression, and the presence 
of stigmata of chronic liver disease. History should include 
details of alcohol intake, risk factors for chronic viral hepa-
titis, use of prescription medication, and over the counter 
or herbal remedies.
Liver biochemistry
The general practitioner requested a repeat serum alanine 
aminotransferase value (which was 58 U/l) and serum 
aspartate aminotransferase and γ glutamyltransferase 
v alues (52 (0-40) U/l and 55 (11-51) U/l respectively).
Raised serum alanine aminotransferase values usually 
indicate hepatocellular damage. Aminotransferase values 
of less than five times the upper limit of normal are often 
considered mild, while those more than five times the upper 
limit of normal are severe, representing more extensive 
hepatocellular injury. Mildly raised values do not exclude 
severe chronic liver disease; indeed evidence exists that 
substantial liver damage may be present even with relatively 
mild biochemical derangements.1 Therefore we recommend 
that even mild derangements of aminotransferase values 
that persist on retesting over a three month period should 
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Suggested pathway for investigating mild to moderately 
raised aminotransferase values (<5 times the upper limit of 
normal). Branch A is recommended if investigations suggest 
non-alcoholic fatty liver disease without comorbidity. Branch 
B is recommended if a case is atypical, if liver comorbidity is 
discovered, or if aminotransferase values do not settle after 
lifestyle modification. Referrals should be considered on a 
case by case basis
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fication of steatosis is considered unreliable.4 An irregular 
liver border and lack of parenchymal homogeneity may 
indicate cirrhosis, and an enlarged spleen may indicate 
portal hypertension.
Outcome
In this patient, the ultrasound scan showed diffusely 
increased echogenicity of the liver consistent with fatty infil-
tration. Given a history negative for high alcohol consump-
tion, these results would be consistent with non-alcoholic 
fatty liver disease.
Non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease is best considered as the 
hepatic manifestation of the metabolic syndrome. The prev-
alence of non-alcoholic fatty liver disease is estimated to be 
20-30% in Western populations.5 Of the patients with the 
disease who have raised aminotransferase levels, 43-55% 
have histological steatohepatitis, and it is these patients 
who are at greatest risk of progressing to cirrhosis.6 
With such a high proportion of the adult population hav-
ing non-alcoholic fatty liver disease, the challenge facing 
clinicians both in primary and secondary care is to identify 
and target treatment at those at greatest risk of cirrhosis 
without the routine need for liver biopsy. Optimum man-
agement remains an area of active research but is probably 
best delivered as a partnership between general practice 
and hepatology services. Associated cardiovascular risk fac-
tors (obesity, hypertension, dyslipidaemia, insulin resist-
ance, and diabetes mellitus) should be sought and tackled 
as these may represent a greater risk to the patient than 
the liver disease. Currently, specialist hepatology referral 
for additional investigation and risk stratification using 
non-invasive biochemical or imaging modalities7  8 (and in 
selected cases liver biopsy) should be considered on a case 
by case basis.6 In patients in whom the results of investiga-
tions are consistent with non-alcoholic fatty liver disease 
and aminotransferase values return persistently to within 
normal ranges on adoption of sustained lifestyle changes, 
onward referral may not be required.
This patient was referred to a hepatologist and seen in 
a subspecialist non-alcoholic steatohepatitis clinic with a 
multidisciplinary team comprising a diabetologist, dieti-
tian, and psychologist to support lifestyle modification 
strategies and compliance. Additionally, he was found 
to have dyslipidaemia, and an oral glucose tolerance test 
showed raised fasting glucose and impaired glucose toler-
ance; he was treated with drugs combined with dietary and 
lifestyle modification. The prevalence of non-alcoholic stea-
tohepatitis with advanced fibrosis is higher among patients 
with a raised alanine aminotransferase value and insulin 
resistance. The “NAFLD (non-alcoholic fatty liver disease) 
fibrosis score”7 based on readily available anthropometric 
and biochemical indices suggested an indeterminate risk 
for advanced fibrosis, and so a liver biopsy was performed 
that confirmed the presence of steatohepatitis with mod-
erate fibrosis, indicating the patient to be of higher risk 
of future liver related morbidity.9 During follow-up the 
patient’s weight reduced to 73 kg and his serum alanine 
aminotransferase value improved, suggesting amelioration 
of the steatohepatitis.
glutamyltransferase values and increased mean cell volume 
are also associated with alcoholic liver disease. 
Full blood count, serum albumin, and prothrombin time/
coagulation tests
Low serum albumin and raised prothrombin time are indic-
ative of impaired hepatic synthetic function, and along with 
low platelet count they suggest hypersplenism and portal 
hypertension resulting from cirrhosis.
Additional tests if liver biochemistry is persistently 
abnormal
There are numerous causes of mildly raised aminotrans-
ferases. The most common are excessive alcohol intake (>14 
units for females and >21 units for males) and obesity lead-
ing to type 2 diabetes mellitus. Singly or in combination, 
these may lead to cirrhosis, often without physical signs 
being present until late in the natural course of the disease. 
No clear evidence exists to guide the timing of testing for 
persistently abnormal liver biochemistry. We suggest wait-
ing three months before doing screening tests to exclude 
less common diagnoses, although this will also clearly 
depend on the clinical context and on availability of test-
ing services. These tests include:
tFor viral hepatitis: hepatitis B surface antigen, and 
hepatitis C antibody 
tFor metabolic disease: ferritin and iron studies to 
exclude haemochromatosis; fasting glucose for 
evidence of diabetes mellitus that may be associated 
with non-alcoholic fatty liver disease.
If the abnormal aminotransferase values persist and the 
initial screening panel is negative, the following investiga-
tions should be undertaken (in practice, these are often 
performed simultaneously):
tFor autoimmune liver disease: antinuclear, smooth 
muscle, liver-kidney microsomal-1 and mitochondrial 
antibodies
tFor α-1 antitrypsin deficiency: serum alpha1-
antitrypsin levels
tFor Wilson’s disease: serum copper and ceruloplasmin 
concentrations.
If screening tests for these conditions are positive, refer-
ral to a hepatologist is advised for confirmatory testing, 
staging, and treatment. The prevalence of chronic hepati-
tis B and C in first generation immigrants of South Asian 
origin in England has been estimated to be 3% and 1.6% 
respectively but varies by country of birth.3 In this patient, 
however, the screening for liver disease did not provide any 
positive results.
Ultrasound scanning
Often liver ultrasonography is arranged in parallel as part 
of the routine assessment of deranged liver function tests. 
Ultrasound scanning is a widespread and economical test 
that enables examination of the liver parenchyma, partic-
ularly for hepatic fat accumulation (steatosis) and exclu-
sion of coincidental common “comorbidities” including 
cholelithiasis. However, it is operator dependent and may 
be technically limited by obesity. Increased echogenicity 
commonly reflects hepatic steatosis, with a sensitivity of 
60%-94% and specificity of 66%-95%; however, quanti-
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A retired general practitioner had hip 
replacements in 1997 and 2009. Here 
she describes the improvements made in 
surgical techniques and case management 
between her two operations
In 2009 I had a left hip replacement, having had a new 
right hip in 1997. Both operations took place in the same 
hospital and were carried out by different surgeons, and 
both have been very successful.
I have nothing but praise for the surgeons and staff who 
cared for me on both occasions. However, the 12 years 
between the operations saw substantial improvements in 
surgical techniques and postoperative case management, 
making the second operation a much more pleasant expe-
rience. This was partly because the orthopaedic technique 
had been improved and refined and is now less invasive 
and so reduces damage to the surrounding muscles. After 
the first operation it was more than a week before I could 
raise the operated leg from the bed, whereas in 2009 I 
could do so on the same day as the operation. For the 
second operation I had a spinal anaesthetic, which made 
the immediate pain control and recovery much better.
However, the most important difference was that in 
2009 the preparation and recovery of hip replacement 
patients were in the hands of a multidisciplinary team 
of specialist orthopaedic nurses, physiotherapists, and 
occupational therapists, rather than only in the hands 
of the surgeon. Specialist orthopaedic nurses had initi-
ated the team approach, and the consultant surgeons had 
agreed to such delegation and compromised on a uniform 
policy of postoperative management. The team members 
shared their different expertise to achieve a united aim of 
quality of care and rapid recovery for patients.
The team approach
After the first consultation with the surgeon I attended a 
“hip school” with several other patients. It lasted about 
an hour, and one of the hip team members explained what 
to expect when coming in to hospital. We were shown x 
ray films of damaged hips and were able to handle exam-
ples of the different types of hip prosthesis. We were each 
measured for crutches and a stick and shown how to use 
them. We were able to borrow the crutches and sticks 
from the hospital, returning them postoperatively when 
the team deemed they were no longer needed. They also 
lent each of us a DVD demonstrating advised exercises 
for before and after the operation. The same information 
was provided in booklet form, along with an invaluable 
list of “dos” and “don’ts” for after the operation. My fel-
low patients and I found the knowledge offered by the hip 
school empowering. It raised our morale and confidence 
and increased our determination to cooperate with each 
other and with the team.
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USEFUL RESOURCES
Rapid Recovery Hip Replacement Programme (www.
hampshire-hip.co.uk)—A video guide to rapid recovery 
after the operation, provided by Basingstoke and North 
Hampshire NHS Foundation Trust
The British Orthopaedic Association (www.boa.ac.uk/en/
patient-liaison/elderlyhip)—Guidance for elderly patients 
with hip fractures
National Joint Registry (www.njrcentre.org.uk)—
Information on hip and knee replacement operations
British Hip Society (www.britishhipsociety.com)—
Homepage of the British Hip Society, including a link to 
download the BHS Hip Replacement Booklet - A Guide For 
Patients
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